• Explore /
  • Poster
  • / FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with <em>KRAS</em> mutated tumors in the randomized German AIO study KRK-0306.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.

Abstract Poster

Authors

Sebastian Stintzing

S. Stintzing

Medical Department III, Klinikum Grosshadern, University of Munich, Munich, Germany

S. Stintzing , J. Neumann , A. Jung , L. Fischer von Weikersthal , T. Decker , U. Vehling-Kaiser , E. Jaeger , T. Heintges , C. Stoll , D. P. Modest , T. Kirchner , V. Heinemann , W. Scheithauer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00433927

Citation

J Clin Oncol 29: 2011 (suppl; abstr 3575)

Abstract #

3575

Poster Bd #

14G

Abstract Disclosures

Similar Posters

First Author: Daniel H. Ahn

First Author: Sotaro Sadahiro

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg